Detailed narrative
Leadership transition: Cordani to Executive Chair, Evanko to CEO on July 1
This was David Cordani's last quarterly earnings call as CEO after nearly 17 years and close to 70 calls. Effective July 1, Brian Evanko (currently President and COO) succeeds him as CEO while Cordani becomes Executive Chair. Evanko framed his focus as making The Cigna Group the clear leader in consumer-focused, AI-enabled health services with an emphasis on clinically complex patients, affordability and personalization.
He committed to strong organic execution, disciplined capital deployment and continued portfolio shaping, and stated he believes the equity has significant appreciation potential from current levels. An Investor Day is planned for September.
Portfolio shaping: two new actions — exit individual exchange and strategic review of EviCore
Management announced it will exit the individual exchange (ACA) business at the end of 2026, supporting members through open enrollment into 2027; drivers were no clear path to scale within Cigna's size and a desire to reduce management focus on a small, shrinking business.
Separately, Cigna initiated a strategic review of alternatives for EviCore, its prior-authorization review business, citing industry-wide standardization/automation progress and the asset's relative scale. Both were described as proactive, not responses to market activity, with no transaction to discuss on EviCore.
These follow prior divestitures of Group Life & Disability and the Medicare businesses (divested last March), and additions of CarePathRx and the Shields Health Solutions investment in specialty.
Evernorth: specialty strength offsets planned PBS decline
Evernorth Q1 revenues grew 9% to $58.4B with pretax adjusted earnings up 2% to $1.5B, slightly ahead of expectations. Specialty & Care Services pretax adjusted earnings rose 20% to $1.1B on solid specialty volume growth, a mix shift to lower-revenue but higher-margin biosimilars/specialty generics, and the Shields investment contribution.
Pharmacy Benefit Services pretax adjusted earnings fell 28% to $394M (~$150M YoY decline) from previously flagged large-client renewals/extensions and Signature build-out investment, with spend weighted to the back half⚖️. Specialty is described as ~35% of company income growing ~12% per year; PBS ~25% of company income.
Signature: transformative rebate-free pharmacy model
Cigna is building a new rebate-free pharmacy benefits model named Signature, positioned to deliver the lowest out-of-pocket cost to consumers — brand drugs 30% lower with full transparency each time — and deeper partnerships with independent/rural pharmacists. A 'price assure' capability guarantees patients the lowest possible out-of-pocket, and if a patient uses a direct-to-consumer cash-pay alternative, that spend applies to their deductible.
Signature becomes the standard model in 2028, with at least 50% of Evernorth PBS members targeted to be in it by year-end 2028. Management met hundreds of its largest PBS clients this week and reports positive feedback; high-cost branded prescriptions are ~10% of scripts but nearly 90% of drug spend.
Cigna Healthcare: MCR beat with prudence maintained
Cigna Healthcare Q1 revenues were $11.5B and pretax adjusted earnings $1.5B, growing 18% YoY. MCR was 79.8%, favorable to the guided ~81% (slightly below), helped by lower flu/respiratory volumes, weather-related care deferrals, and a higher proportion of individual-exchange members in-plan early in the year (lower 1Q MCR).
Management said no single cost category was outsized and that cost trend remains high but has not accelerated. Full-year MCR guidance (83.7%-84.7%) was left unchanged for prudence. Cigna Healthcare was ranked #1 by J.D. Power in digital experience satisfaction among commercial health plan members for a second consecutive year, and its new co-pay-only Clearity medical plan is generating strong market interest.
Data, analytics and AI as an affordability lever
Management emphasized AI across all three platforms — agentic AI in Specialty/Care to speed prescription processing and proactively identify patients; AI in PBS/Signature for member communications and lowest-cost sourcing including GLP-1s; and risk-prediction models in Cigna Healthcare. A predictive high-cost claimant model delivers an average $2,000 per member per year in savings for engaged customers by eliminating unnecessary provider and ER visits, with benefits extending to the stop-loss business.
Combined AI tools and digital experience improvements drove a 20% drop in inbound calls for digitally eligible Cigna Healthcare U.S. Employer customers and a 25% reduction for PBS members vs two years ago. Management stated it does not use AI for clinical decision-making.
Prior authorization reform
Cigna released its first customer transparency report last month and has removed hundreds of tests, procedures and services from prior authorization in the U.S., decreasing medical prior-authorization volume by about 15%. Last week the industry announced further progress on standardizing information required for the most commonly requested procedures, building on voluntary commitments made in June 2025 in coordination with HHS and CMS.
This industry-wide standardization/automation progress was cited as a factor in the decision to review strategic alternatives for EviCore.